Start Free Trial
Pricing
Log In
Log In
Upgrade browser for full Crunchbase experience. You're accessing Crunchbase in a browser that is no longer supported.
Learn More
Maze Therapeutics Logo
Maze Therapeutics Growth Score
67
CB Rank
3351
Heat Score
42
Maze Therapeutics is a biotechnology company that develops precision medicines for renal, cardiovascular, and metabolic diseases.
Founded
obfuscation
PublicPost-IPO Equity South San Francisco, California, United States101-250 www.mazetx.com
Biopharma
Biotechnology
Genetics
Therapeutics
Overview

Maze Therapeutics
Total Funding
obfuscation
Growth Score
67
Heat Score
42

Total Funding
obfuscation
obfuscation
Post-IPO Equity raised
obfuscation
Growth Score67
-12 pts
in past quarter
Heat Score 42
5 pts
in past quarter

Company Performance Metrics

Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Learn More >
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience

About Maze Therapeutics

CB Rank
3351
Maze Therapeutics is a biotechnology company that develops precision medicines for renal, cardiovascular, and metabolic diseases.
Founded
obfuscation
PublicPost-IPO Equity South San Francisco, California, United States101-250 www.mazetx.com
Biopharma
Biotechnology
Genetics
Therapeutics

Funding Rounds

Post-IPO Equity
OBF
in
obfuscation
Post-IPO Equity
OBF
in
obfuscation
Series D
OBF
in
obfuscation

Key People

Details

Legal Name Maze Therapeutics, Inc.
Also Known As Maze
Operating Status Active
Stock Symbol  NASDAQ:MAZE
Company Type For Profit
Founders  Aaron Gitler, Charles Homcy, Jonathan Weissman, Mark Daly, Sekar Kathiresan, Stephen Elledge
About the Company

Maze Therapeutics is a biotechnology company focused on developing medicines that mimic the effects of rare, protective genetic variants to address unmet medical needs. Utilizing its Compass platform, the company identifies genetic variants associated with diseases and maps them to the biological pathways driving these conditions in specific

patient populations.

Contact Email info@mazetx.com
Predictions & Insights

Growth Insight

See this Growth Insight
Maze Therapeutics is
Lorem
 to be growing
Top Contributing Factors
Recently Raised Funding

Growth Prediction

See this Growth Prediction
Top Contributing Factors
Runway Speculation

Products & Services

MZE829 for APOL1 Kidney Disease
A potential oral medicine aimed at protecting the kidneys from APOL1 kidney disease by mimicking the effects of protective genetic variants.
MZE001 for Pompe Disease
An oral substrate reduction therapy in development for the treatment of Pompe Disease, showing potential in reducing glycogen accumulation.

Research & Development

Maze Therapeutics is

obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
...

Unlock More with Crunchbase Pro
  • Full access to financial & funding data on unlimited profiles
  • Export up to 2k results/month for analysis
  • Track market signals on competitors, products, and R&D
  • Preview private company insights and predictions
Financials

Company Funding

Total Funding Amount 
obfuscation
Number of Funding Rounds 6
Unlock company funding data, including rounds, dates, amounts, and investors.
Announced Date  
Transaction Name  
Number of Investors  
Money Raised  
Lead Investors  
Funding Type  
obfuscation
Post-IPO Equity - Maze Therapeutics Logo
Post-IPO Equity - Maze Therapeutics
6
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - Maze Therapeutics Logo
Post-IPO Equity - Maze Therapeutics
6
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - Maze Therapeutics Logo
Post-IPO Equity - Maze Therapeutics
6
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - Maze Therapeutics Logo
Post-IPO Equity - Maze Therapeutics
6
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - Maze Therapeutics Logo
Post-IPO Equity - Maze Therapeutics
6
obfuscation
— Post-IPO Equity

Funding Rounds

Total Funding Amount 
obfuscation
Number of Funding Rounds 6
Unlock company funding data, including rounds, dates, amounts, and investors.
Announced Date  
Transaction Name  
Number of Investors  
Money Raised  
Lead Investors  
Funding Type  
obfuscation
Post-IPO Equity - Maze Therapeutics Logo
Post-IPO Equity - Maze Therapeutics
6
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - Maze Therapeutics Logo
Post-IPO Equity - Maze Therapeutics
6
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - Maze Therapeutics Logo
Post-IPO Equity - Maze Therapeutics
6
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - Maze Therapeutics Logo
Post-IPO Equity - Maze Therapeutics
6
obfuscation
— Post-IPO Equity
obfuscation
Post-IPO Equity - Maze Therapeutics Logo
Post-IPO Equity - Maze Therapeutics
6
obfuscation
— Post-IPO Equity

Investors

Market Intelligence
People
View Profiles & Contacts
Headcount 101-250 Employee Profiles 8 Board Members and Advisors 7 Contacts 108

Employee Profiles

Board Members and Advisors

News

News and Press

News•Jun 3, 2026
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
News•May 13, 2026
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
News•May 7, 2026
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
News•Apr 22, 2026
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
Access a complete feed of recent news and press, from product launches to leadership changes.
Technology
View Tech Report

Monthly Web Visits

12,056
267.9%
 in past month

IT Spend

$1.8MThis year, Maze Therapeutics is projected to spend $1.8M on IT, according to Aberdeen.

Interest Signals

TopicSurge Score
AI PC (Artificial Intelligence Personal Computer) Logo
AI PC (Artificial Intelligence Personal Computer)
100
AI-Powered Search Logo
AI-Powered Search
100
Pillar Two Compliance Logo
Pillar Two Compliance
100

Actively Used Products

14Maze Therapeutics uses 14 technology products and services including HTML5, jQuery, and  Amazon Route 53, according to G2 Stack.

Active Website Tech Count

12Maze Therapeutics is actively using 12 technologies for its website, according to BuiltWith. These include HSTS, DNSSEC, and  Amazon.
Sub-Organizations
Frequently Asked Questions

Where is Maze Therapeutics's headquarters? Maze Therapeutics is located in South San Francisco, California, United States.Who invested in Maze Therapeutics? Maze Therapeutics has 25 investors including Deep Track Capital and  Driehaus Capital Management.When was the last funding round for Maze Therapeutics? Maze Therapeutics closed its last funding round on
obfuscation
from a Post-IPO Equity round.How much funding has Maze Therapeutics raised to date? Maze Therapeutics has raised
obfuscation
.
Who We Are
What We Do
Helpful Links
AI Content may contain mistakes and is not legal, financial or investment advice. Learn more.
Terms of Service | Privacy Policy | Sitemap | © 2026 Crunchbase Inc. All Rights Reserved.
(3ff49e4 1)
|